Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Neurotensin (NTS) is a peptide substance composed of 13 amino acid residues. Since it was first discovered in 1973, it has attracted much attention in many fields of biology and medicine. In the peripheral system, neurotensin mainly functions as a gastrointestinal hormone; in the central nervous system, neurotensin is a multifunctional neurotransmitter or neuromodulator and is associated with a variety of neuropsychiatric diseases.
Figure 1. Neurotensin signalling in colorectal cancer cells. (Shengyang, Q., et al. 2017)
So far, three subtypes of Neurotesin Receptors (NTRs) have been successfully cloned: NTR1, NTR2, and NTR3. In addition, a controversial fourth subtype: NTR4 has been discovered. The two receptor subtypes, NTR1 and NTR2, have been studied the most. In the central nervous system, neurotensin, as a multi-functional neurotransmitter or neuromodulator, mainly regulates dopamine, tryptophan, γ-aminobutyric acid, glutamic acid and the combination of NTR1 and NTR2. The function of the cholinergic system regulates the release of pituitary hormones, inhibits food intake, reduces spontaneous exercise, triggers analgesic effects insensitive to naloxone, and regulates stress-induced analgesia.
The overlapping of anatomical relationship between neurotensin, NTR1 and dopamine and dopamine D2 receptors makes them have a wide range of functional interactions at the cellular level. The study by St-Gelais et al. found that microinjection of neurotensin in the ventral tegmental area in the limbic system of the midbrain can directly increase the discharge of dopaminergic neurons projected into the nucleus accumbens. A recent animal experiment found that the level of dopamine and its metabolite dihydroxy-Phenyl Aceticacid (DOPAC) in the central striatum of neurotensin knockout mice is no different from normal mice. The difference in the above research results shows that the effect of neurotensin on dopamine release varies with the experimental model and the target brain area.
The etiology and pathogenesis of inflammatory bowel disease are currently not fully understood, and immune factors are one of its causes. In recent years, several laboratories have confirmed that the antigen-antibody reaction between NTS and its corresponding receptors in the intestinal mucosa can promote the occurrence of intestinal mucosal inflammation. The levels of NTS in the plasma and intestinal mucosa tissue of patients with ulcerative colitis are lower than that of the control group. NTS binds to NTR1 on the intestinal mucosa to produce biological effects on the intestine. Overexpression of NTR1 was found on the colonic mucosa of mice with experimental inflammatory bowel disease, and the number of NTR1 increased gradually. During the progression of inflammatory bowel disease to colon tumors, NTS and NTR1 have a two-way regulatory effect on colonic mucosal inflammation. Stimulating the production of cytokines and chemokines, between chronic mucosal inflammation and intestinal malignancies, NTS and NTR1 may become unique signals. It stimulates interleukin chemotaxis and leukocyte aggregation, and affects the progression of cancer (including colon cancer) through mitogenic, angiogenic, and single-gene effects.
The study found that NTR1 is expressed in approximately 88% of pancreatic cancer xenografts, and the mRNA level of NTR1 is more highly expressed in advanced pancreatic cancer than early. In terms of pancreatic cancer cell invasion, NTS/NTR1 signaling can stimulate sodium-proton exchanger 1 (NHE1) by activating mitogen-and stress-activated kinase 1/2 (MSK1/2) and the phosphorylation of cAMP response element binding protein (CREB), which makes intracellular alkalization, extracellular acidification, and expression of interleukin 8 (interleukin, IL-8), thereby enhancing its invasion ability and its phenotype transfer. The expression of NTS increases the tumorigenic potential of prostate cancer. It was found that after long-term treatment with LNCaP cells by androgen inhibitors, the expression of NTS and its receptors increased, and the proliferation rate was accelerated, the cell cycle process was accelerated, and the invasive ability was increased, and this effect can be blocked by the siRNA of NTS. The study found that in primary prostate cancer cells, NTR1 is up-regulated in basal phenotype cells, while NTR2 and NTR3 are up-regulated in luminal phenotype cells, indicating that NTRs can be used as targets for the diagnosis of poorly and well differentiated prostate cancer.
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.